Affiliation:
1. Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
Abstract
In light of the unsuccessful traditional therapies for Parkinson’s disease (PD) overmany years, there is an unmet need for the development of novel therapies to alleviate the symptoms of PD retardation or halt the progression of the disease itself. This systematic review aims to critically update some of the most promising novel treatments including gene therapy, cell-based therapies, targeted drug delivery, and neuroprotective agents, focusing on their challenges, limitations and future directions in PD research. Gene therapy in PD is encouraging, with AAV-based approaches targeting neurotrophic factors, dopamine production, and neuronal circuits in animal and clinical trials. A promising approach to targeted drug delivery for PD involves the use of nanotechnology to create drug delivery vehicles that can traverse the blood–brain barrier and deliver medications specifically to the regions of the brain affected by PD. Neuroprotective agents are compounds that have the ability to protect neurons from degeneration and death, and they hold great promise for the evolution of disease-modifying treatments for PD. Magnetic field therapy is a promising non-invasive method that promotes neural plasticity in PD. The establishment of standardized protocols for animal and human studies, safety, ethical considerations, and cost-effectiveness are the major challenges for the future research of novel PD therapies. The development of novel therapies for PD represents a promising path toward to effective personalized disease-modifying treatments for PD.
Reference139 articles.
1. Parkinson disease;Poewe;Nat. Rev. Dis. Primers,2017
2. Direct medical costs associated with Parkinson’s disease: A population-based study;Leibson;Mov. Disord. Off. J. Mov. Disord. Soc.,2006
3. Non-motor symptoms of Parkinson’s disease: Dopaminergic pathophysiology and treatment;Chaudhuri;Lancet Neurol.,2009
4. Motor Complications of Dopaminergic Medications in Parkinson’s Disease;Freitas;Semin. Neurol.,2017
5. Fasano, A., Fung, V.S.C., Lopiano, L., Elibol, B., Smolentseva, I.G., Seppi, K., Takáts, A., Onuk, K., Parra, J.C., and Bergmann, L. (2019). Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol., 19.